Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Does the public know when a scientific controversy is over? Public perceptions of hydroxychloroquine in France between April 2020 and June 2021

Émilien Schultz\textsuperscript{a,b,*}, Laëtitia Atlani-Duault\textsuperscript{a,c,d,e}, Patrick Peretti-Watel\textsuperscript{f,g}, Jeremy K. Ward\textsuperscript{f,h}

\textsuperscript{a} Université de Paris, IRD, Inserm, CEPED (UMR 196), 75006 Paris, France
\textsuperscript{b} Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, ISSPAM, Equipe CANBIOS Labellisée Ligue Contre le Cancer, 13005 Marseille, France
\textsuperscript{c} Institut COVID-19 Add Memoriam, université de Paris, 75006 Paris, France
\textsuperscript{d} WHO Collaborative Center for Research on Health and Humanitarian Policies and Practices, IRD, université de Paris, 75006 Paris, France
\textsuperscript{e} Columbia University, Mailman School of Public Health, New York, NY, USA
\textsuperscript{f} VITROME, Aix-Marseille université, IRD, AP–HM, SSA, 13005 Marseille, France
\textsuperscript{g} Observatoire régional de la santé PACA (ORS Paca), Aix-Marseille université, 13385 Marseille, France
\textsuperscript{h} CERMES3, Inserm, CNRS, EHESS, université de Paris, 94801 Villejuif, France

Reçu le 21 décembre 2021 ; accepté le 10 janvier 2022
Disponible sur Internet le 17 January 2022

**KEYWORDS**
COVID-19 ;
Chloroquine ;
Surveys ;
Public attitude ;
Sociology ;
Hydroxychloroquine

**Summary**

*Objectives.* — In the early stages of the coronavirus disease 2019 (COVID-19) pandemic, chloroquine and its derivatives such as hydroxychloroquine (HCQ) were widely commented upon both within the scientific community and in the media. This paper explores the different factors that influenced public perceptions in France of the efficacy of HCQ as well as their evolution between April 2020 and June 2021.

*Methods.* — This article draws on 5 surveys conducted among representative samples of the French population (projects COCONEL and TRACTRUST; quota method, $n=1006$; 1004; 2006; 1014 and 1005). We asked questions on the effectiveness of chloroquine against COVID-19. We also collected sociodemographic variables and attitudes toward politics and science.
Results. — Between April and June 2021, the proportion of respondents who believed in the efficacy of HCQ decreased rapidly from 35% to 14%. The proportion of respondents who believed that HCQ is ineffective rose gradually from 6% to 21%. After adjusting for the temporal effect, the logistic regression showed a very strong association between political orientation and the belief in the efficacy of HCQ. Respondents who felt closest to the more radical parties (far-right and far-left) were more likely to believe in the efficacy of HCQ than those who felt closest to the political center (O.R. 2.48 [1.95–3.15] and 1.87 [1.44–2.43]). The role of trust in the government and in science and of the degree of political engagement were investigated in the two waves conducted after the scientific consensus was established during the summer of 2020. High levels of trust in the government and in science and of politicization are associated with belief of HCQ proven inefficacy. Across the whole period, a majority of respondents were uncertain. Even in 2021, 41.5% stated that the data were insufficient to decide whether or not HCQ is effective and 25.2% stating that they did not know.

Conclusion. — Because media coverage of scientific controversies is higher in times of uncertainty than after these controversies have died down, the publicization of therapeutic promises can have lasting consequences on attitudes towards science and medicine.

© 2022 L'Auteur(s). Publié par Elsevier Masson SAS au nom de Société française de pharmacologie et de thérapeutique. Cet article est publié en Open Access sous licence CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Abbreviations

AZT azidothymidine
CNRS Centre national de la recherche scientifique
COVID-19 coronavirus disease 2019
HCQ hydroxychloroquine
HIV/AIDS human immunodeficiency virus/acquired immunodeficiency syndrome
IFOP Institut français d’opinion publique
WHO World Health Organization

Introduction

Of all the treatments that have raised and dashed hopes of curing coronavirus disease 2019 (COVID-19), chloroquine and its derivatives, especially hydroxychloroquine (hereafter HCQ) occupies a special place because of the intensity of the debates surrounding it. If it turned out to be ineffective against COVID-19 and even increased mortality when used as a treatment for it [1], HCQ were widely commented upon both within the scientific community and in the media in the early stages of the pandemic. This public debate had several consequences. First, they sent research on unfruitful avenues, as evidenced by the multiplication of clinical trials on HCQ — often of poor quality [2,3] — that yielded negative results [4,5] and by the difficulties in recruiting patients for trials that tested other molecules [6]. Second, several people who took HCQ to treat COVID-19 infection, either through self-medication or prescription, suffered adverse effects [7–9], and patients affected by diseases commonly treated with HCQ (such as malaria or lupus) faced stock-outs due to an explosion of demand for the drug [10]. Third, the debates on HCQ had a temporary impact on health policy in some countries, where exceptional authorizations of use were enacted, and a durable one in others [11,12], such as in Brazil where a “hydroxychloroquine alliance” was formed between intellectuals, physicians, and politicians [13]. Fourth and lastly, the confrontational nature of the debate led to insults and attacks against doctors and scientists on the Internet [14,15] as well as legal actions against scientific advisers to governments, such as in France, accused of mass killing for asking to respect the rules of clinical research.

Because therapeutic promises are generally seen as concerning mainly doctors and patients, the public reception of “new” treatments has so far received little attention in a social pharmacology perspective. The first studies on attitudes towards HCQ have focused mainly on doctors [16]. Few studies, in France or abroad, have explored the factors involved in the formation of public opinion on the efficacy of HCQ. Although the French polling institute “Institut français d’opinion publique” (IFOP) did include a question on perceptions of the efficacy of HCQ in its April 2020 survey showing a very high of respondents believing in the efficacy of HCQ (59%), this has not led to in-depth studies of the factors influencing these perceptions [17]. Outside of France, available studies on the topic were conducted on samples that were not representative of the entire population [18–20].

In this article, we analyze the evolution of the French public’s perceptions of the efficacy of HCQ across a period of more than a year (April 2020–June 2021).

We are particularly attentive to the effects of political orientation and attitudes towards science on public perceptions of the efficacy of HCQ. Indeed, research on public controversies surrounding science suggests that political orientation plays a role in the acceptance or refusal of certain medical technologies [21,22]. More generally, political orientation appears to influence public perceptions of the
scientific consensus [23,24]. This was likely to be the case during the COVID-19 pandemic in France given that many political representatives, on both sides of the political spectrum, became personally involved in advocating for HCQ or defending Professor Didier Raoult, one of the main promoters of HCQ worldwide, based in France [25], and that the debate around this treatment was a major topic in the political news [26]. Available studies also suggest that attitudes towards science are an important factor in the perceived efficacy of certain treatments [27].

After reviewing the evolution of public debates on HCQ in France, this paper explores the different factors that influenced perceptions of the efficacy of HCQ between April 2020 and June 2021 based on 5 surveys conducted on representative samples of the French population. We show that public perceptions of the drug were less polarized than suggested by the media at the time: not only did a large proportion of respondents declare that they were uncertain about the efficacy of HCQ, but levels of uncertainty remained high throughout the study period. We also show that political orientation and trust in science or the government were continuously associated with the belief in the efficacy of HCQ.

They touched upon a variety of issues ranging from the merits of clinical trials, the ethical dilemmas facing doctors in a context of uncertainty, the risk of putting unfounded hopes into new (or old) treatments and the relationship between science, pharmaceutical companies and politicians [26,31].

The mainstream media began to take an interest in this potential treatment after the regional press broadcast the 25 February statement posted by Professor Raoult on the social media accounts of the University Hospital Institute Méditerranée Infection (IHU) [26]. With the gradual recognition of the severity of the COVID-19 pandemic, President Emmanuel Macron announced the lockdown of the country on 16 March, effective the day after. That same day, Professor Raoult posted a video that went viral in which he presented the results of a clinical study by the IHU supporting the efficacy of HCQ. In this context of urgency and uncertainty, the various media widely echoed the ensuing debates, giving voice to a diversity of stakeholders [32]. Internationally, Elon Musk and Donald Trump repeated Professors Raoult’s claims, thereby increasing media coverage of HCQ [10].

In France, media discussions of emerging clinical data on HCQ were accompanied by a political debate. On 3 April, a former Minister of Health, Philippe Douste-Blazy, launched a petition to allow doctors to prescribe the drug. This demand was taken up by different political figures, especially by prominent members of the main conservative party «Les Républicains». Despite the lack of evidence, the acting Minister of Health Olivier Véran issued a decree on 25 March authorizing the prescription of HCQ for serious cases in the hospital setting (2020-314). On 27 March, Professor Raoult posted the results of another IHU study on social networks, and his team continued to promote HCQ for the early management of COVID-19. This high-profile promotion prompted several intellectuals and media personalities to come to the IHU to be treated and to make the case for the drug. Professor Raoult and the IHU gradually entered “pop culture,”

**Evolution of public debates on HCQ in France between April 2020 and June 2021**

While collective mobilizations around potential treatments have occurred in other epidemic contexts — such as azidothymidine (AZT) for HIV [28] — the temporality and scope of the COVID-19 pandemic gave exceptional and international public visibility to the therapeutic promise of HCQ [29]. The debates surrounding HCQ are now considered exemplary of the issues involved in the representation of science in the public sphere [30]. In France, these debates were particularly intense from March to June 2020 (Fig. 1).
both in the form of cultural expressions (tags, paintings, tattoos) and via a very active Facebook group (created on 20 March) that led to intense exchanges on social networks [33]. A mobilization for the generalization of the use of HCQ took place, despite the French government’s reluctance and the COVID-19 Scientific Council’s reminder to respect the rules of clinical research [34]. An IFOP survey reported that at the beginning of April 2020, 98% of French people knew what HCQ was and 59% believed that it was effective against COVID-19 [17]. As more and more clinical data became available, the efficacy of HCQ was increasingly contested by the scientific community. The trajectory of public debates was nevertheless disrupted by what came to be known as the “Lancet gate” scandal. Indeed, a study reporting the high toxicity of HCQ in the Lancet on 22 May was retracted on June 4 for fraudulent data, casting doubt on the growing scientific consensus. While this study had led to the suspension of the World Health Organization (WHO) trials and to the publication on 27 May of a French decree prohibiting the prescription of HCQ for the treatment of COVID-19, its retraction reinforced the positions of HCQ promoters, who loudly denounced the quality of international research. Around the same time, meta-analyses were published that pointed to the inefficacy of HCQ against COVID-19. The intermediate results of the RECOVERY trial published on 5 June showed an absence of effect of HCQ, and the WHO SOLIDARITY trial published on 15 October confirmed this finding [6]. In view of these data, the WHO officially declared HCQ to be ineffective against COVID-19. These events, however, were insufficient to stop some doctors from promoting HCQ in the media, and Professor Raoult continued to defend HCQ on the social media accounts of the IHU and in scientific articles. Nevertheless, the promoters of HCQ became increasingly marginalized, and media coverage of the drug began to decrease (Fig. 1). A recent report by the French National Centre for Scientific Research (Centre national de la recherche scientifique – CNRS) ethics committee criticized the behavior of HCQ promoters, explicitly describing it as a form of scientific populism [35].

Methods

Data collection

This study draws on data from five surveys conducted between 7 April 2020 and 9 June 2021 as part of two research projects funded by Agence nationale de la recherche (ANR). The data were collected by the French Institute of Public Opinion (IFOP) with self-administered online questionnaires sent to representative samples of the adult French population. The representativeness of each samples was attained by quota sampling. Samples were built to match the adult French general population with regards to gender, age, type of professional occupation and population density in the region of residence (as per official census data). The enrollment of respondents continued until the proportions were achieved over two days to a week period. Final adjustments were achieved by weighting. The characteristics of the five surveys are presented in Table 1.

Because public debates on HCQ evolved quite rapidly, we reformulated the main questions and included new variables in the surveys throughout the study. While this limited the comparability of the data, our study nevertheless offers a unique look at the evolution of public perceptions of the efficacy of HCQ in France over more than a year.

In the first two surveys in April, a filter question asked respondents whether or not they knew the chloroquine-based protocol, and a second question asked those who knew this protocol: “In your opinion, is this chloroquine protocol an effective or ineffective treatment against Coronavirus?” Responses options were: “Yes,” “No,” and “I don’t know.” In the last three surveys (June 2020, November 2020 and June 2021), the filter question was no longer asked because the overwhelming majority of French people had heard about HCQ by June 2020. In view of the fact that public debates increasingly focused on the developing scientific consensus, the second question was changed to: “In your opinion, is the current state of knowledge sufficient to settle the scientific debate on the efficacy of chloroquine and its derivatives against the coronavirus?” Responses options were: “Yes, and I think chloroquine and its derivatives are a good treatment against coronavirus,” “Yes, and I think chloroquine and its derivatives are not a good treatment against coronavirus,” “No, I think data are still insufficient” and “I don’t know.”

In accordance with the above questions, public perceptions of the efficacy of HCQ were recoded in the first two surveys into the following three modalities: “belief that HCQ is effective,” “belief that HCQ is ineffective,” and “uncertainty.” In the last three surveys, these perceptions were recoded into the following four modalities: “belief that HCQ is effective,” “belief that HCQ is ineffective,” “uncertainty due to insufficient data,” and “uncertainty due to not knowing.”

The following variables were collected in all five surveys: gender, age, education level, income and political orientation. Given the increasing focus on the developing scientific consensus in public debates, the following variables were collected in the last three surveys: level of politicization, interest and trust in science, and trust in the government.

| Name of the survey | Date of administration | Number of respondents |
|--------------------|------------------------|-----------------------|
| COCONEL1           | 7–9 April 2020         | 1006                  |
| COCONEL2           | 23–27 April 2020       | 1004                  |
| COCONEL3           | 19–24 June 2020        | 2006                  |
| TRACTRUST1         | 13–16 November 2020    | 1014                  |
| TRACTRUST2         | 8–9 June 2021          | 1005                  |
Statistical analysis

Several variables were recoded to ensure comparability and interpretability: “Educational level” was recoded into three groups and “age” was recoded into four groups.

The association between variables was measured using Pearson’s correlation coefficient for numeric variables and the chi-square test for categorical variables. Estimated proportions were interpreted based on the margins of error provided by pooling institutes, which ranged from 1.4 to 3.1 points.

The factors associated with perceptions of the efficacy of HCQ were explored using binomial logistic regression analyses. A theory-driven variable selection was performed. Statistical analyses were conducted using Python (Pandas – Scipy – Statsmodel – PySHS [36]).

Results

A declining belief in the efficacy of hydroxychloroquine with high levels of uncertainty

Following peak media exposure in March 2020 (Fig. 1), almost all respondents had heard about HCQ, with only 7% declaring that they had never heard about it in early April. The majority of respondents were uncertain about the efficacy of HCQ, either due to insufficient data or due to not knowing. Moreover, 35% of respondents believed that HCQ is effective against COVID-19, and 6% believed that it is ineffective (Table 1).

The proportion of respondents who believed in the efficacy of HCQ decreased rapidly from 35% to 20% between April and June 2020. It remained low until June 2021, when 14% of respondents stated that they believed HCQ to be effective. The proportion of respondents who believed that HCQ is ineffective rose gradually from 6% in April 2020 to 21% in June 2021. These findings contrast with the large proportion of respondents who were uncertain about the efficacy of HCQ (either due to insufficient data or due to not knowing), a figure that increased slightly from 60% in April 2020 to 64% in June 2021.

Factors associated with the belief in the efficacy of hydroxychloroquine and their evolution

To account for the main factors associated with the belief in the efficacy of HCQ, we performed a logistic regression on the entire dataset. The dates of each survey were included in the model as covariates (Table 2).

The model showed a strong effect of time on public perceptions of the efficacy of HCQ. After adjusting for this effect, we observed a very strong association between political orientation and the belief in the efficacy of HCQ. All other things being equal, respondents who were close to the more radical parties (far right and far left) were more likely to believe in the efficacy of HCQ than those who were close to the political center (2.48 [1.95–3.15] and 1.87 [1.44–2.43]). Likewise, respondents who were close to the right were more likely to hold this belief than those who were close to the political center (1.43 [1.10–1.85]). Respondents who were not close to any political party were less likely to believe in the efficacy of HCQ compared to those who were close to the political center (0.38 [0.29–0.49]).

Older respondents (above 70 years) were more likely to believe in the efficacy of HCQ than younger ones (below 35 years) (1.36 [1.10–1.69]). Respondents with a high level of education were more likely to believe that HCQ is ineffective than those with a low level of education (1.47 [1.20–1.79]). The models per survey (Supplementary Tables A and B) show that respondents with a high level of education were more likely than those with a low level to believe that HCQ is effective at the beginning of the study period (1.77 [1.27–2.49] for April 2020 survey), but more likely to believe that it is ineffective at the end of this period (1.64 [1.12–2.40] for the June 2021 survey). The effect of political orientation on the belief in the efficacy of HCQ was very strong. Thus, respondents who feel close to far-right parties were more likely than those close to the political center to believe that HCQ is effective at the beginning of the study period (3.33 [1.93–5.73] for the April 2020 survey) and all the way until the end (2.89 [1.43–5.84] for the June 2021 survey). Respondents close to far-left parties were also more likely than those close to the political center to hold this belief from June 2020 onwards (2.44 [1.10–5.37] for the June 2020 survey).

Factors associated with the belief in the efficacy of hydroxychloroquine after the scientific consensus was reached

In June 2020, a scientific consensus on the inefficacy of HCQ began to form (see section on the evolution of public debates). In view of this, specific questions on politicization, interest and trust in science, and trust in the government were included in the November 2020 and June 2021 surveys. The data collected in these two surveys were combined in the binomial logistic model (Table 3).

After the consensus was established, women were less likely than men to believe that HCQ is ineffective (0.63 [0.49–0.82]). Respondents with a high level of education were more likely to believe that HCQ is ineffective (1.62 [1.19–2.21] compared to respondents with a low level of education), as were high-income earners (2.16 [1.13–4.14] compared to low-income earners).

After adjusting for level of politicization, the effect of political orientation disappeared, except for respondents close to the far right, who were less likely than those close to the political center to believe that HCQ is ineffective (0.38 [0.22–0.66]). By contrast, trust in the government had a strong effect on the belief in the efficacy of HCQ. Thus, respondents with a low level of trust in the government were twice as likely to believe that HCQ is ineffective (2.02 [1.46–2.79]) and twice less likely to believe that it is ineffective (0.51 [0.39–0.67]) than those with a high level of trust. The level of politicization also had an effect on the belief in the efficacy of HCQ, as respondents with a high level of politicization were twice as likely to believe in the
### Table 2: Distribution of attitudes toward HCQ (hydroxychloroquine) socio-demographic characteristics and political affiliation.

| Variable          | Modality                  | HCQ is effective (% of the total) | HCQ is ineffective (% of the total) |
|-------------------|---------------------------|-----------------------------------|-------------------------------------|
|                   |                           | 2020-04-07 | 2020-04-23 | 2020-06-19 | 2020-11-13 | 2021-06-08 | 2020-04-07 | 2020-04-23 | 2020-06-19 | 2020-11-13 | 2021-06-08 |
| 1 — Gender        | Man                       | 33.4       | 31.6       | 21.7       | 18.3       | 14.9       | 7.6        | 12.2       | 13.8       | 17.8       | 27.0       |
|                   | Woman                     | 35.7       | 34.0       | 17.9       | 14.8       | 13.8       | 4.0        | 7.8        | 7.7        | 11.4       | 16.2       |
|                   | Total                     | 34.6       | 32.9       | 19.7       | 16.5       | 14.4       | 5.7        | 9.9        | 10.6       | 14.5       | 21.3       |
| 2 — Age           | 17—34                     | 32.0       | 27.8       | 15.3       | 13.3       | 12.6       | 11.4       | 13.3       | 14.1       | 18.9       | 24.1       |
|                   | 35—54                     | 41.9       | 37.1       | 21.2       | 18.9       | 14.5       | 3.8        | 9.0        | 11.2       | 12.4       | 22.7       |
|                   | 55—79                     | 30.5       | 29.7       | 21.6       | 17.1       | 16.8       | 2.7        | 10.3       | 8.4        | 16.2       | 17.6       |
|                   | 70—100                    | 30.7       | 35.8       | 21.5       | 15.4       | 14.0       | 4.0        | 5.4        | 6.4        | 9.1        | 19.0       |
|                   | Total                     | 34.6       | 32.9       | 19.7       | 16.5       | 14.4       | 5.7        | 9.9        | 10.6       | 14.5       | 21.3       |
| 3 — Level of education | 1 — below HS          | 30.0       | 35.9       | 20.4       | 17.1       | 12.5       | 5.6        | 7.9        | 7.7        | 9.4        | 15.4       |
|                   | 2 — HS                    | 40.7       | 35.7       | 21.0       | 17.9       | 17.1       | 6.3        | 8.3        | 10.4       | 14.7       | 22.1       |
|                   | 3 — over HS               | 38.6       | 25.9       | 17.8       | 14.6       | 15.7       | 5.7        | 14.3       | 15.5       | 22.6       | 30.2       |
|                   | Total                     | 34.6       | 32.9       | 19.7       | 16.5       | 14.4       | 5.7        | 9.9        | 10.6       | 14.5       | 21.3       |
| 4 — Income        | 1 — 0—1000€               | 37.1       | 34.0       | 19.2       | 22.2       | 19.8       | 12.3       | 11.8       | 11.6       | 7.7        | 14.1       |
|                   | 2 — 1000—2000€            | 38.1       | 36.6       | 17.9       | 18.7       | 14.4       | 6.1        | 8.3        | 7.1        | 16.3       | 17.5       |
|                   | 3 — 2000—4000€            | 36.3       | 31.2       | 21.8       | 14.5       | 14.8       | 4.9        | 11.4       | 9.9        | 11.0       | 23.0       |
|                   | 4 — 4000€ and more        | 27.2       | 25.4       | 15.5       | 10.1       | 12.8       | 5.8        | 11.4       | 24.6       | 25.9       | 32.0       |
|                   | 5 — NA                    | 25.2       | 36.0       | 21.0       | 18.0       | 11.8       | 3.5        | 5.7        | 7.5        | 16.1       | 18.9       |
|                   | Total                     | 34.6       | 32.9       | 19.7       | 16.5       | 14.4       | 5.7        | 9.9        | 10.6       | 14.5       | 21.3       |
| 5 — Political orientation | 1 — Center             | 28.0       | 30.2       | 15.4       | 11.1       | 11.1       | 9.0        | 12.6       | 16.6       | 17.7       | 45.4       |
|                   | 2 — None                  | 29.6       | 26.2       | 14.2       | 12.8       | 9.9        | 2.0        | 5.6        | 7.4        | 10.4       | 15.2       |
|                   | 3 — Left                  | 39.9       | 32.4       | 17.8       | 17.4       | 10.4       | 8.6        | 13.8       | 18.2       | 25.8       | 26.7       |
|                   | 4 — Right                 | 31.9       | 30.5       | 22.0       | 23.5       | 18.7       | 3.2        | 11.9       | 13.7       | 16.0       | 20.8       |
|                   | 5 — Far-left              | 36.3       | 39.0       | 30.3       | 23.2       | 23.0       | 12.3       | 8.0        | 9.0        | 24.5       | 23.6       |
|                   | 6 — Far-right             | 55.2       | 55.3       | 30.1       | 21.2       | 24.7       | 7.0        | 14.0       | 4.3        | 5.6        | 11.1       |
|                   | 7 — Other                 | 22.3       | 5.6        | 24.5       | 5.6        | 17.7       | 10.1       | 9.9        | 19.6       | 5.6        | 32.9       |
|                   | Total                     | 34.6       | 32.9       | 19.7       | 16.5       | 14.4       | 5.7        | 9.9        | 10.6       | 14.5       | 21.3       |
Table 3  Binomial logistic regressions of the answers regarding HCQ (over the 5 surveys).

| Variable         | Modality | HCQ is effective |           |           |           | HCQ is ineffective |           |           | Uncertain |           |           |
|------------------|----------|-------------------|-----------|-----------|-----------|---------------------|-----------|-----------|-----------|-----------|-----------|
|                  |          | Odds ratio        | P         | IC 95%    | Odds ratio | P         | IC 95%    | Odds ratio | P         | IC 95%    |
| Intercept        |          | 0.36              | 0.0***    | 0.36 [0.26–0.50] | 0.17 | 0.0***    | 0.17 [0.11–0.26] | 1.12 | 0.434 | 1.12 [0.84–1.50] |
| 1 — Genre        | Man      | 0.98              | 0.771     | 0.98 [0.86–1.11] | 0.61 | 0.0***    | 0.61 [0.51–0.72] | 1.27 | 0.0*** | 1.27 [1.14–1.42] |
|                  | Woman    | 1.51              | 0.0***    | 1.51 [1.28–1.78] | 0.64 | 0.0***    | 0.64 [0.52–0.78] | 0.92 | 0.242 | 0.92 [0.80–1.06] |
| 2 — Age          | 17–34    | 1.29              | 0.009**   | 1.29 [1.07–1.57] | 0.58 | 0.0***    | 0.58 [0.45–0.73] | 1.09 | 0.319 | 1.09 [0.92–1.28] |
|                  | 35–54    | 1.36              | 0.005**   | 1.36 [1.10–1.69] | 0.42 | 0.0***    | 0.42 [0.31–0.56] | 1.18 | 0.08  | 1.18 [0.98–1.42] |
|                  | 55–79    | 1.32              | 0.001**   | 1.32 [1.11–1.56] | 1.14 | 0.263     | 1.14 [0.91–1.44] | 0.77 | 0.001** | 0.77 [0.66–0.89] |
|                  | 70–100   | 1.15              | 0.095     | 1.15 [0.98–1.34] | 1.47 | 0.0***    | 1.47 [1.20–1.79] | 0.74 | 0.0*** | 0.74 [0.65–0.85] |
| 3 — Level of education | 1 — below HS | 0.93              | 0.527     | 0.93 [0.73–1.17] | 0.88 | 0.427     | 0.88 [0.64–1.21] | 1.13 | 0.267 | 1.13 [0.91–1.39] |
|                  | 2 — HS   | 1.15              | 0.095     | 1.15 [0.98–1.34] | 1.47 | 0.0***    | 1.47 [1.20–1.79] | 0.74 | 0.0*** | 0.74 [0.65–0.85] |
|                  | 3 — over HS | 0.84              | 0.13      | 0.84 [0.66–1.05] | 0.89 | 0.445     | 0.89 [0.65–1.21] | 1.21 | 0.065 | 1.21 [0.99–1.49] |
|                  | 1 — 0-1000€ | 0.61              | 0.001**   | 0.61 [0.45–0.83] | 1.39 | 0.07      | 1.39 [0.97–2.00] | 1.16 | 0.268 | 1.16 [0.89–1.49] |
| 4 — Income       | 2 — 1000-2000€ | 0.89              | 0.432     | 0.89 [0.68–1.18] | 0.88 | 0.517     | 0.88 [0.60–1.29] | 1.15 | 0.27  | 1.15 [0.90–1.47] |
|                  | 3 — 2000-4000€ | 0.93              | 0.511     | 0.93 [0.74–1.16] | 0.38 | 0.0***    | 0.38 [0.29–0.49] | 1.71 | 0.0*** | 1.71 [1.42–2.05] |
|                  | 4 — 4000€ and more | 1.23              | 0.108     | 1.23 [0.96–1.59] | 0.95 | 0.723     | 0.95 [0.73–1.24] | 0.88 | 0.244 | 0.88 [0.72–1.09] |
|                  | 5 — NA   | 1.43              | 0.007**   | 1.43 [1.10–1.85] | 0.7  | 0.019*    | 0.70 [0.52–0.94] | 0.94 | 0.6   | 0.94 [0.76–1.17] |
|                  | 1 — Center | 1.87              | 0.0***    | 1.87 [1.44–2.43] | 0.71 | 0.028*    | 0.71 [0.52–0.96] | 0.76 | 0.018* | 0.76 [0.61–0.95] |
| 5 — Political orientation | 2 — None | 2.48              | 0.0***    | 2.48 [1.95–3.15] | 0.36 | 0.0***    | 0.36 [0.26–0.50] | 0.76 | 0.011* | 0.76 [0.62–0.94] |
|                  | 3 — Left | 0.79              | 0.457     | 0.79 [0.42–1.48] | 0.67 | 0.228     | 0.67 [0.34–1.29] | 1.49 | 0.12  | 1.49 [0.90–2.46] |
|                  | 6 — Survey          | 0.93              | 0.259     | 0.90 [0.74–1.08] | 1.81 | 0.001**   | 1.81 [1.28–2.55] | 0.93 | 0.408 | 0.93 [0.77–1.11] |
|                  | 1 — early April 2020 | 0.44              | 0.0***    | 0.44 [0.37–0.52] | 1.98 | 0.0***    | 1.98 [1.45–2.69] | 1.63 | 0.0*** | 1.63 [1.39–1.91] |
|                  | 2 — end April 2020 | 0.34              | 0.0***    | 0.34 [0.28–0.43] | 2.95 | 0.0***    | 2.95 [2.13–4.08] | 1.58 | 0.0*** | 1.58 [1.31–1.90] |
|                  | 3 — June 2020 2020 | 0.3              | 0.0***    | 0.30 [0.24–0.37] | 4.76 | 0.0***    | 4.76 [3.48–6.52] | 1.25 | 0.016* | 1.25 [1.04–1.51] |

HCQ: hydroxychloroquine; HS: high school; *** : P<0.001; ** : P<0.01; * : P<0.05.
efficacy of HCQ than those with a low level of politicization (1.85 [1.32–2.59]).

Trust in science also appeared to have an effect, as those with a low level of trust were twice as likely to believe that HCQ is effective than those with a high level of trust (2.20 [1.61–3.02]). Respondents who had no interest in science were twice less likely to accept the scientific consensus that HCQ is ineffective than those who did (0.62 [0.47–0.81]).

The importance of uncertainty

By the end of 2020 and during 2021, the majority of respondents were uncertain about the efficacy of HCQ, with 41.5% stating that the data were insufficient to decide whether or not HCQ is effective and 25.2% stating that they did not know. While political orientation, level of politicization, trust in science, and trust in the government determined the ratio between the belief that HCQ is effective and the belief that it is ineffective, uncertainty consistently remained the majority option (Fig. 2).

The factors associated with uncertainty due to insufficient data were not the same as those associated with uncertainty due to not knowing (Table 3). Indeed, the factors that distinguished respondents who stated that they were uncertain due to insufficient data were a high level of trust in science (0.68 [0.52–0.90] compared to respondents with a low level of trust in science) and a high income (1.75 [1.20–2.55] compared to low-income earners). By contrast, several factors were associated with uncertainty due to not knowing: being a woman (1.45 [1.14–1.83] compared to men), having a high level of education (0.61 [0.45–0.81] compared to respondents with a low level of education), feeling close to no party (1.87 [1.18–2.96] compared to respondents close to the political center), and having a low level of politicization (0.61 [0.46–0.82] compared to respondents with a high level of politicization). Having no interest in science (1.96 [1.08–3.57] compared to respondents with an interest in science) and answering "don’t know" to the question on trust in the government (1.96 [1.08–3.57]) or trust in science (5.51 [3.20–9.50]) were also associated with uncertainty due to not knowing.

Discussion

The controversy over HCQ will long remain a cautionary tale for researchers [29], as it brought to the fore the limits of pre-publications, the dangers of publicizing certain studies, and the importance of conducting high-quality clinical trials. The treatment of the scientific controversy by journalists, intellectuals, scientists, and political representatives is also a case study on how to publicly discuss medical treatments, and more generally scientific research, in a context of uncertainty [26]. Within the scientific community, the
handling of the controversy reignited a number of debates on questions of publication and citation and more generally on public perceptions of medical research [30]. While it is necessary to draw lessons from this episode for the conduct of research, whose temporality does not correspond to that of the media [37], the scope and intensity of the debates on HCQ also highlight the importance of better understanding their public reception.

Have the urgency of the COVID-19 pandemic and the desire to believe in a cure resulted in a polarization between promoters and opponents of HCQ? The IFOP survey published on April 6, 2020, found that 59% of French people believed in the efficacy of HCQ, which suggested that the enthusiasm for this treatment was strong in the early stages of the pandemic [17]. The survey that we conducted one week later showed that only one third of respondents considered HCQ effective against COVID-19, reflecting a rapid decline in this enthusiasm. Yet, peaks in demand for HCQ and in internet searches do not mean that everyone was carried away by hope, even though many may have initially been seduced by this therapeutic promise. Indeed, while our April 2020 survey also found a high proportion of respondents who were uncertain about the efficacy of the drug. Moreover, perceptions of HCQ evolved rapidly over the study period.

From the beginning of the study period, there was a very strong association between political orientation and the belief that HCQ is effective. Respondents close to the far-right, and later also those close to the right or the far-left, were more likely to hold this belief than those close to the political center. This could be an effect of the political opposition to the governmental policies, but this finding may also be explained by the fact that political figures of the right and far-right defended HCQ [26] as part of their criticism of the government’s handling of the crisis and its refusal to authorize this promising treatment. Another possible explanation is that HCQ was largely promoted on social media accounts associated with the right and the far right [33]. The politicization of HCQ is also reflected in the fact that respondents with no political orientation were more likely to state that they were unsure about its efficacy.

The results of the November 2020 and June 2021 surveys (Table 4) shed light on the effects of politicization and attitudes towards science. The association between level of politicization and the belief that HCQ is effective suggests that perceptions of the drug were largely rooted in a political reading of the government’s handling of the crisis. Trust in science diminished the likelihood of believing that HCQ is effective and, conversely, increased the likelihood of believing that it is ineffective. This is consistent with the existing literature, particularly on vaccination, which shows that attitudes towards science, and more generally towards institutions, has an effect on the perception of new medical technologies [38,39]. Yet, while the effect of trust in science was strong in our study (at a factor of nearly 2), it does not fully explain perceptions of HCQ among the French public.

Our five surveys show a gradual decline in the number of respondents who believed in the efficacy of HCQ and an increase in the number of respondents who believed in its inefficacy. Those who continued to defend this treatment even after the scientific consensus was reached had the lowest levels of trust in institutions and the government, and were unsurprisingly largely associated with the political parties most opposed to the government. Thus, in June 2021, 45% of respondents who were close to the political center believed that HCQ is ineffective, vs. only 11% among those close to the far right held this belief. This difference may be explained by differentiated uses of information sources, with alternative media and social networks pursuing the campaign in support of HCQ and Professor Raoult. Another possible explanation is the persistence of the memory of the controversy among respondents with the lowest levels of trust in institutions and the government. Importantly, the proportion of respondents who believed in the efficacy or the inefficacy of HCQ (i.e. respondents who had an opinion on the drug) and that of respondents who were uncertain about its efficacy remained stable throughout the study period. These findings indicate that perceptions of the drug were not overly polarized, and therefore highlight the importance of measuring uncertainty to avoid artificially polarizing analyses.

Our analysis of public perceptions of HCQ call into question the idea that belief in fallacious ideas is the product of low levels of education. While having a high level of education was associated in our study with having an opinion on HCQ (as opposed to being uncertain), this opinion was not necessarily in line with the developing scientific consensus, especially in the early stages of the pandemic. Conversely, a low level of education was associated not so much with the belief in the efficacy of HCQ, but with not knowing whether or not HCQ is effective. When studying public perceptions of controversies, it is important to take into consideration the fact that different social groups have very different levels of engagement with media debates. As studies on ordinary relations to politics have shown [40], one of the main social divides in France is that between, on the one hand, people whose cultural practices connect them to the public sphere and who have positive attitudes towards institutions, and, on the other hand, people who are not connected to the public sphere and who display much lower levels of trust in the state and its actors [41].

This debate also raises the question of the reception of therapeutic promises in the public sphere. The recall of episodes from the HIV/AIDS epidemic during the COVID-19 pandemic shows that controversies surrounding some treatments, or medical technologies more generally, can have durable effects on social representations [31]. On a longer time frame, HCQ has been used massively in the fight against malaria in former French colonies including northern African countries. Part of the French population might have perceived Professor Raoult, born in Senegal and raised by a French doctor who promoted HCQ against malaria, as the last of a long list of colonial and post-colonial heroes of “state vertical humanitarianism” allowing him to call into question necessity and quality of contemporary scientific norms [24,43] and as such didn’t question his promotion of HCQ in a time of health humanitarian crisis.

Insofar as the debates on HCQ gave visibility to different conceptions of science and to the problems of knowledge production in biomedical research — as evidenced by the “Lancet gate” scandal, which seems to have been a turning point, and by the multiplication of working papers of varying quality — the high levels of uncertainty observed in our study can easily be instrumentalized towards a critique of institutions. Several studies have shown that the
| Variable         | Modality   | HCQ is effective | HCQ is ineffective | Knowledge is uncertain | Don’t know |
|------------------|------------|------------------|--------------------|------------------------|------------|
|                  |            | P IC 95%         | P IC 95%           | P IC 95%               | P IC 95%   |
| Intercept        | Man        | 0.0*** 0.10 [0.05–0.21] | 0.015* 0.41 [0.20–0.84] | 0.008** 0.49 [0.29–0.83] | 0.0*** 0.25 [0.13–0.48] |
| 01 – Gender      | Woman      | 0.936 0.99 [0.76–1.29] | 0.0*** 0.63 [0.49–0.82] | 0.619 1.05 [0.87–1.27] | 0.002** 1.45 [1.14–1.83] |
| 02 – Age         | 17–34      | 0.075 1.36 [0.97–1.92] | 0.271 0.84 [0.62–1.15] | 0.55 0.93 [0.73–1.18] | 0.947 1.01 [0.76–1.35] |
|                  | 35–54      | 0.258 1.25 [0.85–1.86] | 0.165 0.77 [0.53–1.11] | 0.211 1.20 [0.90–1.58] | 0.158 0.78 [0.55–1.10] |
|                  | 55–79      | 0.655 1.11 [0.70–1.77] | 0.015* 0.58 [0.38–0.90] | 0.096 1.31 [0.95–1.81] | 0.857 1.04 [0.70–1.53] |
|                  | 70–100     | 0.304 1.20 [0.85–1.70] | 0.162 1.29 [0.90–1.83] | 0.539 1.08 [0.84–1.41] | 0.008** 0.65 [0.47–0.89] |
| 03 – Level of education | 1 – below HS | 0.356 1.17 [0.84–1.63] | 0.003** 1.61 [1.18–2.20] | 0.752 0.96 [0.76–1.22] | 0.001** 0.61 [0.45–0.81] |
|                  | 2 – HS      | 0.063 0.64 [0.40–1.03] | 0.084 1.67 [0.93–2.99] | 0.122 1.35 [0.92–1.97] | 0.135 0.73 [0.48–1.11] |
|                  | 3 – over HS  | 0.003** 0.49 [0.30–0.78] | 0.339 1.32 [0.74–2.35] | 0.003** 1.75 [1.20–2.55] | 0.162 0.74 [0.49–1.13] |
|                  | 1 – 0–1000€ | 0.046 0.65 [0.38–1.12] | 0.045* 1.92 [1.02–3.62] | 0.045* 0.63 [0.41–0.99] | 0.06 1.55 [0.98–2.45] |
| 05 – Political orientation | 2 – None   | 0.487 0.83 [0.49–1.40] | 0.007** 0.57 [0.38–0.86] | 0.702 1.07 [0.76–1.50] | 0.008** 1.87 [1.18–2.96] |
|                  | 3 – Left    | 0.66 0.88 [0.50–1.55] | 0.883 0.97 [0.64–1.48] | 0.873 1.03 [0.71–1.49] | 0.533 1.18 [0.70–1.99] |
|                  | 4 – Right   | 0.175 1.47 [0.84–2.55] | 0.113 0.69 [0.43–1.09] | 0.346 0.83 [0.56–1.22] | 0.081 1.60 [0.94–2.70] |
|                  | 5 – Far left | 0.118 1.59 [0.89–2.86] | 0.999 1.00 [0.61–1.63] | 0.848 0.96 [0.63–1.47] | 0.364 0.75 [0.40–1.40] |
|                  | 6 – Far right | 0.146 1.50 [0.87–2.59] | 0.001** 0.38 [0.22–0.66] | 0.345 1.20 [0.82–1.76] | 0.39 1.26 [0.75–2.12] |
|                  | 7 – Other   | 0.466 0.58 [0.13–2.52] | 0.204 0.46 [0.14–1.53] | 0.233 1.70 [0.71–4.07] | 0.316 1.72 [0.60–4.94] |
| 06 – Level of polarization | 1 – Low    | 0.777 1.06 [0.73–1.53] | 0.071 1.37 [0.97–1.93] | 0.349 1.13 [0.88–1.46] | 0.015* 0.69 [0.51–0.93] |
|                  | 3 – High    | 0.0*** 1.85 [1.32–2.59] | 0.507 1.12 [0.81–1.54] | 0.702 0.95 [0.75–1.21] | 0.001** 0.61 [0.46–0.82] |
| 07 – Trust in government | 2 – No   | 0.0*** 2.02 [1.46–2.79] | 0.0*** 0.51 [0.39–0.67] | 0.615 1.06 [0.85–1.31] | 0.618 1.07 [0.82–1.39] |
|                  | 3 – Yes     | 0.274 0.48 [0.13–1.80] | 0.506 0.74 [0.31–1.77] | 0.224 0.69 [0.37–1.26] | 0.027* 1.96 [1.08–3.57] |
| 08 – Interest in science | 2 – No     | 0.588 0.93 [0.70–1.22] | 0.001** 0.62 [0.47–0.81] | 0.601 1.05 [0.86–1.29] | 0.003** 1.43 [1.13–1.82] |
|                  | 3 – Yes     | 0.47 [0.17–1.26] | 0.007** 0.19 [0.06–0.63] | 0.006** 0.68 [0.52–0.90] | 0.75 0.95 [0.69–1.31] |
| 09 – Trust in science | 2 – No   | 0.0*** 2.20 [1.61–3.02] | 0.122 0.72 [0.47–1.09] | 0.006** 0.68 [0.52–0.90] | 0.75 0.95 [0.69–1.31] |
|                  | 3 – Yes     | 0.132 0.47 [0.17–1.26] | 0.007** 0.19 [0.06–0.63] | 0.006** 0.68 [0.52–0.90] | 0.75 0.95 [0.69–1.31] |

HCQ: hydroxychloroquine; ***: P<0.001;**: P<0.01;* : P<0.05.
correction of false information has less effect than its initial communication [44]. Public controversies allow for the instrumentalization of scientific knowledge [45] and that moments of intense public debate have lasting effects since doubts about their actual outcome can be remobilized later to defend certain positions — as illustrated by the case of vaccine hesitancy [39]. Moreover, uncertainty can encourage distrust in the efficacy (or inefficacy) of certain treatments and can push part of the public towards the most radical forms of complementary and alternative medicine. This is a major concern given that alternative treatments can also contribute to the propagation of conspiracy theories [20].

Conclusion
While the controversy over HCQ is not the first nor the last to emerge surrounding a new but ultimately disappointing treatment [46,47], it received enormous media coverage in the early stages of the COVID-19 pandemic in France. After the scientific consensus on the inefficacy of HCQ was reached, public health authorities issued statements that were clear and readily available, but that received little attention in public debates. Because media coverage of scientific controversies is typically higher in times of uncertainty than after these controversies have died down, the publicization of therapeutic promises can have lasting consequences on attitudes towards science and medicine [48], and this despite the existence of fact-checking activity. Researchers should take into consideration this asymmetry when publicly discussing medical treatments or vaccines [49], and more generally scientific research, in a context of uncertainty.

Acknowledgement
The surveys were conducted thanks to two projects funded by the Agence Nationale de la Recherche (ANR): COCONEL (ANR-20-COVI-0035-01, dir. Patrick Peretti-Watel) and TRACTRUST (ANR-20-COVI-0102, dir. Laëtitia Atlani-Duault). The COCONEL survey was approved by the ethics committee of the IHU (#2020-018) and the TRACTRUST survey by the IRB of the Biomedical Research Institute INSERM CEI (#20-722). We are grateful to Arianne Dorval for her editorial assistance in this article translation.

Disclosure of interest
L. A.-D.: member of the French "Conseil scientifique COVID-19". Other authors declare that they have no competing interest.

Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.therap.2022.01.008.

Références
[1] Axfors C, Schmitt AM, Janiaud P, van’t Hooft J, Abd-Elsalam S, Abdo EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun 2021;12:1–13.
[2] Quinn TJ, Burton JK, Carter B, Cooper N, Dwan K, Field R, et al. Following the science? Comparison of methodological and reporting quality of covid-19 and other research from the first wave of the pandemic. BMC Med 2021;19:1–10.
[3] Roustit M, Guilhamou R, Molimard M, Drici MD, Laporte S, Montastruc J-L. Chloroquine and hydroxychloroquine in the management of COVID-19: much kerfuffle but little evidence. Therapie 2020;75:363–70.
[4] Sourimant J, Aggarwal M, Plemer RK. Progress and pitfalls of a year of drug repurposing screens against COVID-19. Curr Opin Virol 2021;49:183–93.
[5] Pearson H. How COVID broke the evidence pipeline. Nature 2021;593:182–5.
[6] Gould S, Norris SL. Contested effects and chaotic policies: the 2020 story of (hydrox) chloroquine for treating COVID-19. Cochrane Database Syst Rev 2021;3 [ED000151].
[7] Gérard A, Romani S, Fresse A, Viard D, Parassol N, Granvillene A, et al. “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapie 2020;75:371–9.
[8] Perez J, Roustit M, Lepelley M, Revol B, Cracowski JL, Khouri C. Reported adverse drug reactions associated with the use of hydroxychloroquine and chloroquine during the COVID-19 pandemic. Ann Intern Med 2021;174:827–80.
[9] Tucconi M, Conventino I, Ferraro S, Cappello E, Valdiserra G, Focosi D, et al. The impact of the COVID-19 "Infodemic" on drug-utilization behaviors: implications for pharmacovigilance. Drug Saf 2020;43:699–709.
[10] Liu M, Caputi TL, Dredze M, Kesselheim AS, Ayers JW. Internet searches for unproven COVID-19 therapies in the United States. JAMA Intern Med 2020;180:1116–8.
[11] Boschiero MN, Capasso Palamini CV, Ortega MM, Mauch RM, Lima Marson FA. One year of coronavirus disease 2019 (COVID-19) in Brazil: a political and social overview. Ann Glob Health 2021;87:44.
[12] Belayneh A. Off-label use of chloroquine and hydroxychloroquine for COVID-19 treatment in Africa against WHO recommendation. Res Rep Trop Med 2020;11:61–72.
[13] Casarões G, Magalhães D. The hydroxychloroquine alliance: how far-right leaders and alt-science preachers came together to promote a miracle drug. Rev Adm Publica 2021;55:197–214, https://www.scielo.br/j/rap/a/b3DhgtmpWBFZMdSNqDY6Ht/. [Accessed 10 January 2022].
[14] Peiffer-Smادja N, Rebade MD, Guilhur A, Mahamat-Saleh Y, Fiolet T. Hydroxychloroquine and COVID-19: a tale of populism and obscurantism. Lancet Infect Dis 2021;21:e121.
[15] Ektorp E. Death threats after a trial on chloroquine for COVID-19. Lancet Infect Dis 2020;20:661.
[16] Lutaud R, Scronias D, Ward J, Verger P. The hydroxychloroquine debate: a therapeutic dilemma for general practitioners. Eur J Public Health 2021;31:283–5.
[17] IFOP pour Labtoo. Rapport d’étude. L’opinion des Français sur la chloroquine et la recherche de traitements contre le coronavirus; 2020. https://www.ifop.com/wp-content/uploads/2020/04/117231_rapport_ifop_labtoo_chloroquine_2020_04_05.pdf. [Accessed 10 January 2022 (12 pp)].
[18] Osuagwu UL, Nwaeeze O, Ovenseri-Ogbono G, Oluruntoba R, Ekpenyong B, Mashihe KP, et al. Opinion and uptake of
chloroquine for treatment of COVID-19 during the mandatory lockdown in the sub-Saharan African region. Afr J Prim Health Care Fam Med 2021;13(1):e1–8.
[19] Endriyas M, Kawza A, Alano A, Hussen M, Mekonnen E, Samuel T, et al. Knowledge and attitude towards COVID-19 and its prevention in selected ten towns of SHRP Region, Ethiopia: Cross-sectional survey. PLoS One 2021;16:e0255884.
[20] Bertin P, Nera K, Delouvée S. Conspiracy beliefs, rejection of vaccination, and support for hydroxychloroquine: a conceptual replication-extension in the COVID-19 pandemic context. Front Psychol 2020;11:565128.
[21] Ward JK, Alleaume C, Peretti-Watel P, COCONEL group. The French public’s attitudes to a future COVID-19 vaccine: The politicization of a public health issue. Soc Sci Med 2020;265:113414.
[22] Eyal G. The crisis of expertise. Cambridge, United Kingdom: Polity Press; 2019, 206p.
[23] Mann M, Schleifer C. Love the science, hate the scientists: conservative identity protects belief in science and undermines trust in scientists. Soc Forces 2020;99:305–32.
[24] Gauchat G. Politicization of science in the public sphere: a study of public trust in the United States, 1974 to 2010. Am Sociol Rev 2012;77:167–87.
[25] Chemin A, Etchegoin M-F, Raoult. Une folie française. Paris (France): Gallimard; 2021.
[26] Schultz É, Ward JK. Science under Covid-19’s magnifying glass: Lessons from the first months of the chloroquine debate in the French press. J SocioL 2022;58. https://journals.sagepub.com/doi/10.1177/1440783321999453. [Accessed 10 January 2022].
[27] Boy D. Les représentations sociales des thérapies innovantes. Quaerendi 2013;81:61–76. https://journals.openedition.org/quaerendi/712. [Accessed 10 January 2022].
[28] Epstein S. Impure science. AIDS, activism and the politics of knowledge. Berkeley: University of California Press (USA); 1996, 480 p. ISBN: 0520214455, 9780520214453.
[29] Battu SE, Liew JW, Graef ER, Coler-Reilly A, Berenbaum F, Duarte-Garcia A, et al. Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert Rev Clin Immunol 2020;16:659–66.
[30] Caulfield T, Bubela T, Kimmelman J, Rivotsky V. Let’s do better: public representations of COVID-19 science. Facets 2021;6:403–23 [https://www.facetsjournal.com/doi/10.1139/facets-2021-0018].
[31] Berlivet L, Löwy I. Hydroxychloroquine controversies: clinical trials, epistemology, and the democratization of science. Med Anthropol Q 2020;34:525–41.
[32] Bayet A, Hervé N. Comment Didier Raoult et la chloroquine ont péri dans le traitement médiatique du coronavirus. INA La revue des médias; 2020. https://larevuedesmedias.ina.fr/etude-coronavirus-covid19-traitement-mediatique-raoult-chloroquine. [Accessed 10 January 2022].
[33] Smyrnaios N, Tsimboukis P, Loubère L. La controverse autour de Didier Raoult et de sa proposition thérapeutique contre le Covid-19 sur Twitter: analyse de réseaux et de discours. Commun Rev Commun Soc publice 2021;31:1–20, http://journals.openedition.org/communiquer/8309. [Accessed 10 January 2022].
[34] Conseil scientifique COVID-19. Avis du Conseil scientifique COVID-19 du 2 avril 2020. État des lieux du confinement et critères de sortie; 2020. https://www.vie-publique.fr/rapport/274080-avis-conseil-scientifique-covid-2-avril-2020-confinement-criteres-sortie. [Accessed 10 January 2022].
[35] COMETS/CNRS. Communication scientifique en situation de crise sanitaire: profusion, richesse et dérives; 2021. https://comite-ethique.cnrs.fr/avis-du-cometes-communication-scientifique-en-situation-de-crise-sanitaire-profusion-richesse-et-derives/. [Accessed 10 January 2022].
[36] Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, et al. “SciPy 1.0: fundamental algorithms for scientific computing in Python”. Nat Methods 2020;17:261–72 [https://www.nature.com/articles/s41592-019-0686-2/].
[37] Tummino TA, Rezelj VV, Fischer B, Fischer A, O’Meara MJ, Monel B, et al. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. Science 2021;373:541–7.
[38] Schultz É, Ward JK, Atlani-Duault L, Holmes SM, Mancini J. French public familiarity and attitudes toward clinical research during the COVID-19 pandemic. Int J Environ Res Public Health 2021;18:2611.
[39] Dubé É, Ward JK, Verger P, Macdonald NE. Vaccine hesitancy, acceptance, and anti-vaccination: trends and future prospects for public health. Annu Rev Public Health 2020;42:175–91.
[40] Buton F, Lehnigue P, Mariot N, Rozier S. L’ordinaire du politique. Enquêtes sur les rapports profanes au politique. (Villeneuve d’Ascq, France): Presses universitaires du Septentrion; 2016. Collection Paradoxa. 410 p. ISBN: 2757414739.
[41] Spire A. 2. La confiance dans l’État : une relation pratique et symbolique. In: Crises de confiance ? Paris: La Découverte; 2020, p. 37–55. https://www.cairn.info/crises-de-confiance-9782348065866-page-37.htm. [Accessed 10 January 2022].
[42] Atlani-Duault L, Chauvin F, Yazdanpanah Y, Lina B, Benamouzig D, Boudama L, et al. France’s COVID-19 response: balancing conflicting public health traditions. Lancet 2020;396:219–21.
[43] Atlani-Duault L, Dozon JP, Wilson A, Delfrais SY, Moota JP. State humanitarian verticalism versus universal health coverage: a century of French international health assistance revisited. Lancet 2016;387:2250–62.
[44] Walter N, Murphy ST. How to unring the bell: a meta-analytic approach to correction of misinformation. Commun Monogr 2018;85:423–41.
[45] Oreskes N, Conway EM. Merchants of doubt: How a handful of scientists obscured the truth on issues from tobacco smoke to global warming. USA: Bloomsbury Publishing; 2011. ISBN: 1608192938, 9781608192939.
[46] Dalgalarrondo S, Hauray B. Les économies de la promesse anti-âge. Le cas de la DHEA. Soci Sci Sante 2015;33:5–30. https://www.cairn.info/revue-sciences-sociales-et-sante-2015-2-page-5.htm. [Accessed 10 January 2022].
[47] Dalgalarrondo S, Hauray B. Conflit d’intérêts et traitements anti-Alzheimer: de la construction à la contestation d’une promesse médicale. Soci Sci Sante 2020;38(3):77–104 [https://www.cairn.info/revue-sciences-sociales-et-sante-2020-3-page-77.htm].
[48] Bauer MW, Pansegrau P, Shukla R. The cultural authority of science. (London, United Kingdom): Routledge; 2018, 420 p. ISBN 9781138059924.
[49] Montastruc JL, Lafaurie M, de Canaduce C, Montastruc F, Bagheri H, Durrieu G, et al. COVID-19 vaccines: a perspective from social pharmacology. Therapie 2021;76:311–5.